Clinical Trial

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-31
Trial Details
NCT Number NCT07406334
Lead Sponsor GlaxoSmithKline
Conditions Pneumonia, Bacterial
Enrollment 45 participants
Start Date 2026-05-15
Primary Completion 2027-02-22 (estimated)
Study Completion 2027-02-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-30